New Hypertension Drug Baxdrostat Successfully Lowers Blood Pressure in Patients Resistant to Standard Treatments

UCL-led trial shows baxdrostat reduces blood pressure by 10 mmHg in resistant patients. A breakthrough for the 1.3 billion people living with hypertension.

By: AXL Media

Published: Apr 4, 2026, 9:35 AM EDT

Source: Information for this report was sourced from ScienceDaily

A Major Breakthrough for Treatment-Resistant Hypertension

Medical researchers have identified a powerful new pharmacological tool in the global fight against uncontrolled high blood pressure. In a Phase III clinical trial involving nearly 800 patients across 214 global clinics, a medication known as baxdrostat proved highly effective in lowering blood pressure for individuals who had previously seen no success with existing drugs. The study, led by Professor Bryan Williams of the University College London (UCL) Institute of Cardiovascular Science, addressed a critical gap in care for the estimated 1.3 billion people worldwide living with hypertension, many of whom remain at high risk for cardiovascular events despite ongoing treatment.

The Strategic Suppression of Excess Aldosterone

The clinical success of baxdrostat lies in its unique ability to target aldosterone, a hormone responsible for regulating the body's salt and water balance. In many difficult-to-treat cases, an overproduction of this hormone causes the body to retain excessive salt and water, which in turn drives blood pressure to dangerous levels. While previous medical efforts to manage this hormonal imbalance have struggled, baxdrostat works by directly blocking the production of aldosterone. This targeted approach offers a fresh perspective on the underlying causes of resistant hypertension, providing a solution that specifically addresses the biological mechanics of the condition.

Quantifying the Impact on Cardiovascular Risk

The results of the BaxHTN trial, published in the New England Journal of Medicine, revealed that patients taking either 1 mg or 2 mg doses of the pill experienced a systolic blood pressure drop of approximately 10 mmHg more than the placebo group. According to Professor Williams, this specific level of reduction is clinically significant, as it is directly linked to a substantially lower risk of heart failure, stroke, kidney disease, and heart attacks. Furthermore, 40 percent of the participants taking the medication were able to reach healthy blood pressure targets, doubling the success rate seen in the control group.